Based on the PPI network and KEGG enrichment analysis, a set of ten hub genes (GAPDH, AKT1, CASP3, GSK3B, EGFR, STAT3, ESR1, MMP9, NFκB1, and MTOR) and five potential targets (BACE1, CDK5, ADAM17, CDK5R1, and MME) have been recognized as having involvement in the neuroprotective effects on AD-associated with MS. This evidence concerns the gene NFKB1 and myeloid sarcoma.